Colossal Biosciences in Talks at $20B–$30B Valuation
24 Jul 2026
Colossal Biosciences, the five-year-old startup best known for its de-extinction research, is reportedly in talks for a new funding round that could value the company at $20 billion to $30 billion — up from its previous valuation of $10.2 billion. The talks come roughly 16 months after that earlier valuation was revealed.
What's happening
According to the report, Colossal has started generating revenue over the last year, a shift from its earlier research-heavy profile. The company has also spun out three startups — Breaking, Form Bio, and Astromech — as part of a broader strategy that appears to be diversifying its business beyond core de-extinction work.
Numbers tied to that spinout strategy stand out:
- Astromech was valued at $2 billion as of March.
- Form Bio secured $30 million in its own funding.
- The UAE invested $60 million directly in Colossal Biosciences, with the U.S. government also named as a relevant party to the company's operations or investment — though the report does not specify the government's exact role.
Colossal also plans to spin off its artificial animal womb technology, which could have applications in human fertility treatment. Founder Lamm said in May that the technology is expected to be ready next year.
Why the numbers matter
The jump from a $10.2 billion valuation to talk of $20–$30 billion in just 16 months is a steep climb, and the report flags that this could reflect speculative market interest rather than confirmed financial performance. It's not yet clear whether the round has been finalized or is still in early discussions, nor which investors are leading it.
Why founders should care
- Founders in deep-tech or biotech sectors may find it increasingly plausible that spinning out subsidiary businesses can unlock additional valuation — Astromech's $2 billion mark and Form Bio's $30 million raise suggest this model is gaining traction, though it's unclear how repeatable this is outside Colossal's specific platform.
- The involvement of a sovereign investor (UAE's $60 million stake) may indicate growing international appetite for U.S. biotech ventures, a trend worth watching if you're courting foreign capital.
- Colossal's pivot toward revenue generation after years of pure R&D could be an early signal that investors are pushing deep-tech companies to monetize faster — founders building long R&D-cycle products should probably expect similar pressure.
- The planned artificial womb spinout, with potential human fertility applications, is a reminder that technology built for one purpose can create new regulatory and ethical exposure when it moves into adjacent, more sensitive markets.
Risks and open questions
The report is careful to note several unresolved risks:
- The valuation jump may be driven more by market enthusiasm than by audited financials.
- Heavy reliance on spinouts for value creation could leave Colossal exposed if its core de-extinction business underperforms.
- Government and foreign (UAE) involvement may invite regulatory or geopolitical scrutiny.
- The artificial womb technology, given its potential human fertility use case, could face ethical, regulatory, or safety hurdles before it ever reaches spinout stage.
Key details remain missing from the current record: who is leading the new round, the exact nature and scale of Colossal's new revenue streams, the full scope of U.S. government and UAE involvement beyond the $60 million investment, whether the round has closed, and total funds raised to date across all of Colossal's rounds.
For now, Colossal's trajectory — from a $10.2 billion company to one reportedly in talks at triple that valuation — is one of the more striking valuation stories in biotech this year, but much of the underlying detail is still not public.